These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1497 related items for PubMed ID: 11496232

  • 1. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N.
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J.
    Curr Med Res Opin; 2001 Aug; 17(4):233-40. PubMed ID: 11922396
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD, Omalizumab 011 International Study Group.
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H.
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [Abstract] [Full Text] [Related]

  • 8. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M.
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 10. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A.
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [Abstract] [Full Text] [Related]

  • 11. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [Abstract] [Full Text] [Related]

  • 12. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
    Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ.
    N Engl J Med; 1999 Dec 23; 341(26):1966-73. PubMed ID: 10607813
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K, Miyamoto T, Amagasaki T, Yamamoto M, 1304 Study Group.
    Respirology; 2009 Nov 23; 14(8):1156-65. PubMed ID: 19909462
    [Abstract] [Full Text] [Related]

  • 14. Omalizumab is effective in the long-term control of severe allergic asthma.
    Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N.
    Ann Allergy Asthma Immunol; 2003 Aug 23; 91(2):154-9. PubMed ID: 12952109
    [Abstract] [Full Text] [Related]

  • 15. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G.
    Eur Respir J; 2001 Aug 23; 18(2):254-61. PubMed ID: 11529281
    [Abstract] [Full Text] [Related]

  • 16. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW, Massanari M, Kianifard F, Geba GP.
    Curr Med Res Opin; 2007 Oct 23; 23(10):2379-86. PubMed ID: 17711616
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.